CMC Biologics A/S, a contract provider of clinical and commercial manufacturing of monoclonal antibodies and other therapeutic proteins, and IDT Biologika GmbH, a privately held life-science company with expertise in research, development and manufacture of biologics for human and animal health, have formed a strategic collaboration to provide a complete solution for the manufacture of antibody drug conjugates (ADCs).

Within this collaboration, CMC Biologics will perform process development and manufacture of the bulk monoclonal antibody, and IDT Biologika will perform services from conjugation of the cytotoxic drug to the antibody substance through to the aseptic fill, finish, and packaging of the ADC final drug product. This joint manufacturing solution is intended to provide speed, reliability, quality ADC manufacturing, and a simplified supply chain, from DNA to finished drug product, for clinical trials through commercial manufacturing.

Additional details will be provided at DCAT Week ’16 in March 2016, and initial services will become available to clients in April 2016, according to the companies.

Source: CMC Biologics and IDT Biologika